… to evaluate the efficacy and safety of treatment with molnupiravir started within 5 days after
… , laboratory-confirmed Covid-19 and at least one risk factor for severe Covid-19 illness. …

… filing related to oral dosage forms, … orally effective COVID-19 treatment. The authors
believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment…

… -2 oral drugs (nirmatrelvir/ritonavir and molnupiravir), (iii) summarizes the clinical progress of
other oral antivirals for use in COVID-19, (iv… with the use of oral antivirals in clinical practice. …

… treatment completely blocked transmission to untreated animals, emphasizing that early
treatment … for 5 days in the treatment of patients with mild to moderate COVID-19. Hypotheses …

… by many countries for the treatment of coronavirus disease 2019 (Covid-19). However, the …
oral antiviral agent with potent activity against severe acute respiratory syndrome coronavirus …

… of influenza and is being explored more for its role in the treatment of COVID-19. It is the first
oral antiviral drug approved for mild to moderate COVID-19. The already completed studies …

… are at high risk for severe Covid-19 and associated adverse … severe Covid-19 and five times
as likely to die from Covid-19 … A need exists for safe and effective oral Covid-19 treatments …

… syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus (… In this regard, one of the
helpful drugs for the treatment is … as a novel oral anti-viral drug for the treatment of COVID-19 [4]. …

… neurological-based oral sensations, etc. As specific pharmacological treatment for COVID-19
is still … for potential treatment of severe COVID-19 complications. They comprise remdesivir, …

… In this study, EIDD-2801 was used as BID, 12 and 36 h after infection by oral gavage. Also,
the effect of molnupiravir on blocking contact transmission was investigated (in the control …